Michael  Castagna net worth and biography

Michael Castagna Biography and Net Worth

CEO of MannKind

Michael Castagna is the CEO of MannKind Corporation, a role he has held since March 2016. He also serves on the company’s board of directors.

MannKind is a biopharmaceutical company focused on discovery, development, and commercialization of therapeutics for diseases like diabetes and pulmonary arterial hypertension. In his role as CEO, Dr. Castagna is focused on strategic development of the company’s people and products.

Dr. Castagna had a 14-year career as a pharmacist with CVS before fully transitioning to the business side of the industry. Before joining MannKind, he held various executive positions at Merck Serono, Sandoz, Pharmasett, Bristol-Myers Squibb, and most recently, Amgen, where he served as vice president, global commercial lead for a portfolio of nine biosimilar drugs.

While at BMS, he helped lead the relaunch of Orencia IV and the launch of Orencia SC, both drugs targeting rheumatoid arthritis. At Sandoz, he helped relaunch its lead product, a human growth hormone called Omnitrope. 

In his free time, Castagna serves on the board of directors of Pet Partners, a nonprofit organization with a mission of improving people’s health through positive interactions with therapy animals. 

He earned his B.S. in pharmacy from the University of the Sciences in Philadelphia, his M.B.A. in entrepreneurial studies from the University of Pennsylvania’s Wharton School of Business, and his doctor of pharmacy degree from the Massachusetts College of Pharmacy and Health Sciences.

What is Michael Castagna's net worth?

The estimated net worth of Michael Castagna is at least $10.28 million as of December 14th, 2023. Dr. Castagna owns 2,239,147 shares of MannKind stock worth more than $10,277,685 as of May 20th. This net worth evaluation does not reflect any other investments that Dr. Castagna may own. Additionally, Dr. Castagna receives a salary of $1,530,000.00 as CEO at MannKind. Learn More about Michael Castagna's net worth.

How old is Michael Castagna?

Dr. Castagna is currently 47 years old. There are 9 older executives and no younger executives at MannKind. Learn More on Michael Castagna's age.

What is Michael Castagna's salary?

As the CEO of MannKind Co., Dr. Castagna earns $1,530,000.00 per year. Learn More on Michael Castagna's salary.

How do I contact Michael Castagna?

The corporate mailing address for Dr. Castagna and other MannKind executives is 30930 RUSSELL RANCH ROAD SUITE 300, WESTLAKE VILLAGE CA, 91362. MannKind can also be reached via phone at (818) 661-5000 and via email at [email protected]. Learn More on Michael Castagna's contact information.

Has Michael Castagna been buying or selling shares of MannKind?

Michael Castagna has not been actively trading shares of MannKind during the last ninety days. Most recently, Michael Castagna sold 110,000 shares of the business's stock in a transaction on Thursday, December 14th. The shares were sold at an average price of $4.00, for a transaction totalling $440,000.00. Following the completion of the sale, the chief executive officer now directly owns 2,239,147 shares of the company's stock, valued at $8,956,588. Learn More on Michael Castagna's trading history.

Who are MannKind's active insiders?

MannKind's insider roster includes Steven Binder (CFO), Michael Castagna (CEO), Alejandro Galindo (Insider), David Thomson (EVP), and Stuart Tross (Insider). Learn More on MannKind's active insiders.

Are insiders buying or selling shares of MannKind?

In the last twelve months, insiders at the biopharmaceutical company sold shares 13 times. They sold a total of 550,104 shares worth more than $2,472,279.96. The most recent insider tranaction occured on May, 13th when EVP Steven B Binder sold 3,618 shares worth more than $15,593.58. Insiders at MannKind own 3.0% of the company. Learn More about insider trades at MannKind.

Information on this page was last updated on 5/13/2024.

Michael Castagna Insider Trading History at MannKind

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/14/2023Sell110,000$4.00$440,000.002,239,147View SEC Filing Icon  
11/1/2023Sell10,000$4.25$42,500.002,349,147View SEC Filing Icon  
10/2/2023Sell10,000$4.61$46,100.002,359,147View SEC Filing Icon  
9/1/2023Sell10,000$4.61$46,100.002,436,039View SEC Filing Icon  
8/1/2023Sell10,000$4.57$45,700.002,496,735View SEC Filing Icon  
7/3/2023Sell10,000$4.07$40,700.002,506,735View SEC Filing Icon  
6/1/2023Sell10,000$4.53$45,300.002,516,735View SEC Filing Icon  
5/26/2023Sell75,000$4.50$337,500.002,526,735View SEC Filing Icon  
5/24/2023Sell150,000$4.69$703,500.002,331,735View SEC Filing Icon  
5/5/2023Sell10,000$4.00$40,000.002,020,128View SEC Filing Icon  
4/3/2023Sell10,000$4.13$41,300.002,030,128View SEC Filing Icon  
3/1/2023Sell10,000$5.27$52,700.002,040,128View SEC Filing Icon  
7/31/2022Buy3,147$2.93$9,220.712,084,486View SEC Filing Icon  
7/30/2021Buy5,000$2.99$14,950.00View SEC Filing Icon  
3/5/2021Buy3,000$3.38$10,140.00View SEC Filing Icon  
6/15/2020Buy30,000$1.49$44,700.00198,560View SEC Filing Icon  
6/12/2020Buy68$1.41$95.88198,560View SEC Filing Icon  
1/31/2019Buy5,000$1.07$5,350.0098,157View SEC Filing Icon  
8/2/2018Buy5,000$1.31$6,550.0068,157View SEC Filing Icon  
12/20/2017Buy8,000$2.29$18,320.0035,532View SEC Filing Icon  
8/26/2016Buy17,500$0.78$13,650.00212,500View SEC Filing Icon  
8/24/2016Buy15,000$0.87$13,050.00195,000View SEC Filing Icon  
8/23/2016Buy25,000$0.94$23,500.00180,000View SEC Filing Icon  
8/12/2016Buy25,000$1.00$25,000.0075,000View SEC Filing Icon  
5/17/2016Buy50,000$0.93$46,500.0050,000View SEC Filing Icon  
See Full Table

Michael Castagna Buying and Selling Activity at MannKind

This chart shows Michael Castagna's buying and selling at MannKind by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

MannKind Company Overview

MannKind logo
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
Read More

Today's Range

Now: $4.59
Low: $4.51
High: $4.61

50 Day Range

MA: $4.41
Low: $4.05
High: $4.92

2 Week Range

Now: $4.59
Low: $3.17
High: $5.75


2,119,500 shs

Average Volume

2,800,918 shs

Market Capitalization

$1.25 billion

P/E Ratio


Dividend Yield